Pulmozyme.com site quick analysis
Share your opinion about Pulmozyme.com:
Search engine results page snippet (SERP)
This is how Pulmozyme.com appears when you search for it:
pulmozyme.com
Find information about cystic fibrosis and Pulmozyme, including how to manage your cystic fibrosis, your CF treatments, and options for financial support. INDICATION Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics. IMPORTANT SAFETY INFORMATION Pulmozyme should not be used in patients who are allergic to any of its ingredients. Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived. Pediatric Use The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection. The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to < 5 years (younger group) and 33 aged 5 years to < 10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.
General website information
A quick breakdown about the Pulmozyme.com website can be found further down:
Aspect | Summary |
---|
Website load speed: | 2.4036s poor |
Number of (outgoing) links: | 37 |
HTML size: | 28.6 kilobytes Good |
meta-tag Generator | Drupal 7 (http://drupal.org) |
Pulmozyme.com HTTP headers
HTTP/1.0 301 Moved Permanently
Location: http://www.pulmozyme.com/
Server: BigIP
Connection: Keep-Alive
Content-Length: 0
IP address in detail
The following domains are, too, hosted on 72.34.128.236:
Keywords
A total of 11 keywords are used by the website
- pulmonary function
- mucus in lungs
- dornase alfa
- Genentech
- CF
- cystic fibrosis symptoms
- cystic fibrosis
- lung function
- CF treatment
- pulmozyme cost
- pulmozyme
List of related IP addresses
Based on A and B block, the following IP adresses are similar to 72.34.128.236
Domain extension options
The following domain extensions are available for the domain name, with a total of 730 variations available:
Global Alexa rating
As mentioned by Alexa on their official page, the Alexa rank or rating is calculated using a number of different parameters, such as daily average of unique visitors as well as pageviews over the last three months. The more unique visitors and pageviews, the higher the overall rank.
Unfortunately, our database contains no Alexa rank data for Pulmozyme.com at this time.
Website domain mistypes
Visitors frequently mistype pulmozyme.com.
Here is a list of most common misspellings:
Domain history
It seems pulmozyme.com has only been registered once and was never abandoned or has never expired.
Rating by Quantcast
Established in 2006, the technology company Quantcast provides audience measurements and an opportunity for advertising in real time. In addition to that, the American company ensures public access to all sorts of website-related data (traffic and demographic) for millions of websites, as well as in-depth user insights to digital bloggers and publishers enrolled in Quantcast's Quantified Publisher Program. The processing capability provided by Quantcast is impressive – over 800 thousand transactions per second, with, as claimed by the company, accurate audience calculation for over 100 million online destinations. In 2013, Quantcast was widely believed to be among the top five of world's largest data processing companies. Holding offices in London, Dublin, New York and Chicago, the main headquarters of Quantcast is in San Francisco, CA.
Pulmozyme.com
Current rating: | spotted 3,733 days ago |
---|
Worst rating: | spotted 3,809 days ago |
---|
Best rating: | spotted 3,735 days ago |
---|
Average rating: | |
---|